Perspective Therapeutics, Inc. CATX
0.94 USD +0.10 (+11.95%)
Regular-session close
0.97 +0.03 +2.75%
After hours · Nov 13, 6:24 PM ET
0.8544 Day range 0.9661
0.7864 52-week range 5.65
- YTD
- -65.71%
- 1 year
- -54.44%
News
benzinga.com Truist Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $8 Truist Securities analyst Gregory Renza maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target from $11 to $8.
benzinga.com Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results Perspective Therapeutics Inc (NYSE:CATX) on Monday posted a narrower loss for the third quarter.
benzinga.com Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results Perspective Therapeutics narrowed its Q3 loss to $0.27/share, but sales fell. Analysts cut price targets, sending shares down 2.4%.
benzinga.com Wedbush Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $7 Wedbush analyst David Nierengarten maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target from $9 to $7.
benzinga.com Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $8 Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $14 to $8.
globenewswire.com Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results SEATTLE, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
globenewswire.com Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 SEATTLE, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
benzinga.com Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across…
globenewswire.com Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs SEATTLE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…- benzinga.com RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4 RBC Capital analyst Leonid Timashev downgrades Perspective Therapeutics (AMEX:CATX) from Outperform to Sector Perform and lowers the price target from $14 to $4.
marketbeat.com Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update Perspective Therapeutics NYSEAMERICAN: CATX presented updated clinical data for its VMT-α-NET program at the European Society for Medical Oncology Congress 2026, reporting tumor responses, an…
benzinga.com Perspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced systemic treatments
globenewswire.com Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs SEATTLE, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
benzinga.com Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle…
globenewswire.com Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
defenseworld.net Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "buy" rating reiterated by BTIG Research in a research note issued on Wednesday, Benzinga reports. They currently have a…- benzinga.com BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
globenewswire.com Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
defenseworld.net Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) has received an average recommendation of "Buy" from the eleven brokerages that are presently covering the stock, Marketbeat…
benzinga.com Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026 Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
globenewswire.com Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
benzinga.com Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
benzinga.com Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
benzinga.com This $3 Biotech Could Be Worth $11.45, Analyst Says Perspective Therapeutics Inc. (NYSE:CATX) could benefit from growing interest in radiopharmaceutical cancer treatments, according to William Blair.
benzinga.com This $3 Biotech Could Be Worth $11.45, Analyst Says William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
benzinga.com William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating.- benzinga.com Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
- benzinga.com Perspective Therapeutics Enters Clinical Trial Collaboration With Merck To Combine Its PSV359 With Keytruda Under An Amendment To Ongoing Phase 1/2A Study Of PSV359 In Patients With Certain Types Of Non-Small Cell Lung Cancer And Colorectal Cancer Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for
globenewswire.com Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
globenewswire.com Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company…
seekingalpha.com Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans Perspective Therapeutics remains a “Strong Buy,” driven by durable clinical data and multiple near-term catalysts across its radiopharmaceutical pipeline. The company's bamzireotide navoxetan for…- benzinga.com BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11 BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
- benzinga.com B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5 B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
defenseworld.net Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX Dimensional Fund Advisors LP raised its holdings in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 391.6% during the first quarter, according to the company in its most recent 13F filing with…
zacks.com Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year? Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
zacks.com 4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
defenseworld.net Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 88.4% in the undefined quarter, according to its most recent Form 13F filing with the…
benzinga.com Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 up 100 pts. Telefonaktiebolaget LM Ericsson falls 9.2% in pre-market. Other stocks moving lower in pre-market.
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Earnings Scheduled For March 16, 2026
benzinga.com This Tempus AI Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com Earnings Scheduled For August 13, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Earnings Scheduled For May 12, 2025